Nuvation Bio has one commercial asset Ibtrozi for ROS1 NSCLC. Their second asset Safusidenib for high-grade glioma, is in clinical trials which can be found here Clinical Trials. The latest positive news from Nuvation comes as they have received net proceeds of $277.6 million, from an oversubscribed convertible notes offering due 2032. Positives from the just completed notes offering below.
- Retired older, high interest debt of $55.8 million
- $17.1 million used for capped call options, hedge to $10.458
- At present, is non-diluting to shareholders
- Added new cash of around $205 million after all deductions
- Multi-year cash runway now available
The new cash infusion will be used to fund clinical development, and general corporate purposes. Weekly chart of Nuvation below, thank you for reading.
Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.
